Literature DB >> 1751354

Psoriasis induced by interferon-alpha.

J Funk1, T Langeland, E Schrumpf, L E Hanssen.   

Abstract

Recombinant human interferon-alpha has been used in the treatment of several cancers, but there have been several reports that it may exacerbate psoriasis or trigger off its onset. We report four patients, three of whom first developed psoriasis and one who had an aggravation of the condition during treatment with interferon-alpha. Three of the patients had the carcinoid syndrome and one a renal carcinoma, and all were treated with interferon-alpha 2b or 2a (IFN-alpha 2b, 2a) with doses ranging from 1.5 x 10(6) U daily to 18 x 10(6) U three times weekly. In two of the patients there appeared to be a correlation between the severity of the psoriasis and the dosage of interferon.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1751354     DOI: 10.1111/j.1365-2133.1991.tb14774.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  28 in total

Review 1.  Tolerability of treatments for viral hepatitis.

Authors:  A Gervais; N Boyer; P Marcellin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Induction and exacerbation of psoriasis with Interferon-alpha therapy for hepatitis C: a review and analysis of 36 cases.

Authors:  M Afshar; A D Martinez; R L Gallo; T R Hata
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-06-01       Impact factor: 6.166

3.  Inhibition of a C-rich oligodeoxynucleotide on activation of immune cells in vitro and enhancement of antibody response in mice.

Authors:  Guang Yang; Min Wan; Yongsheng Zhang; Luguo Sun; Ran Sun; Dali Hu; Xiaojing Zhou; Li Wang; Xiuli Wu; Liying Wang; Yongli Yu
Journal:  Immunology       Date:  2010-12       Impact factor: 7.397

4.  Antimicrobial Peptide LL37 and MAVS Signaling Drive Interferon-β Production by Epidermal Keratinocytes during Skin Injury.

Authors:  Ling-Juan Zhang; George L Sen; Nicole L Ward; Andrew Johnston; Kimberly Chun; Yifang Chen; Christopher Adase; James A Sanford; Nina Gao; Melanie Chensee; Emi Sato; Yi Fritz; Jaymie Baliwag; Michael R Williams; Tissa Hata; Richard L Gallo
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

Review 5.  Immune responses and therapeutic options in psoriasis.

Authors:  Inna S Afonina; Elien Van Nuffel; Rudi Beyaert
Journal:  Cell Mol Life Sci       Date:  2021-01-02       Impact factor: 9.261

Review 6.  [Interferon therapy and autoimmunity].

Authors:  J Fritzsch; J Krug; H J Heberling
Journal:  Med Klin (Munich)       Date:  1997-05-15

Review 7.  How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets.

Authors:  Virginia Pascual; Florence Allantaz; Pinakeen Patel; A Karolina Palucka; Damien Chaussabel; Jacques Banchereau
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

Review 8.  Peginterferon alfa related psoriasis in a patient with acute hepatitis C and review of the literature.

Authors:  Muhammed Sait Dag; Zeynel Abidin Oztürk; Nimet Yılmaz; Hakan Cam; Abdurrahman Kadayıfçı
Journal:  Wien Klin Wochenschr       Date:  2013-08-03       Impact factor: 1.704

9.  Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.

Authors:  P Vedak; D Kroshinsky; J St John; R J Xavier; V Yajnik; A N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2016-01-24       Impact factor: 8.171

Review 10.  Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection.

Authors:  E D'Amico; M Paroli; V Fratelli; C Palazzi; V Barnaba; F Callea; G Consoli
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.